Abstract
An embryonic toxicity of Rhizoma sparganii was observed in mice. This study was aimed to evaluate the anticancer effects of Grailsine-Al-glycoside, the bioactive component of Rhizoma sparganii, on estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) cancer cell lines. After A549, HeLa, HepG-2 and MCF-7 cells were treated with Grailsine-Al-glycoside, cell proliferation was analyzed by MTT, cell cycle and apoptosis by flow cytometry, and morphology with an immunofluorescence microscope. Grailsine-Al-glycoside strongly suppressed cell proliferation in a dose-dependent fashion in A549, MCF-7, HepG2, and HeLa cells, though this growth inhibitory effect on HepG2 cells was not as strong and long lasting. Compared to the control, Grailsine-Al-glycoside caused a significant increase of apoptosis in A549, MCF-7 and Hela cells. A549 and MCF-7 cells were arrested at the G2/S phase whereas HepG2 cells were arrested at the G1 phase by a high concentration of Grailsine-Al-glycoside . Cell shapes were also changed by the presence of Grailsine-Al-glycoside. Grailsine-Al-glycoside from Rhizoma sparganii inhibited the proliferation of ER+ and some ER- cancer cells. Grailsine-Al-glycoside may be used as a chemotherapeutic agent against ER+ and ERRα-expressing ER- cancers.
Highlights
Erratum This article [1] has been retracted by the Editor
The authors informed the Editor that they are unable to reproduce key data presented in the article
The Editor has been unable to confirm with Northwest University whether an institutional investigation has taken place
Summary
Erratum This article [1] has been retracted by the Editor.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
